GPS Maintenance Therapy in AML Remission

Trial
32%16%0%Jun 16Jun 17Jun 18Jun 19Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 24 • YES 22.0%Jun 25 • YES 0.1%
Stock ($SLS)
No stock close$9.43$8.35$7.27Jun 16Jun 17Jun 18Jun 19Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 16 • SLS $7.53Jun 17 • SLS $7.76Jun 18 • SLS $8.05Jun 22 • SLS $8.53Jun 23 • SLS $9.07Jun 24 • SLS $9.17

Will this trial show a positive result on overall survival for GPS versus best available therapy?

Create account to trade
Primary Completion
11/30/26
Study Completion
12/1/26
Sponsor
SELLAS Life Sciences Group
Ticker
$SLS
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
127
NCT
NCT04229979
Trial Description
GPS is being tested as AML maintenance therapy; this market resolves on statistically significant overall survival success by Nov. 30, 2026.